Adjunctive therapies in chronic lung disease: Examining the evidence

Seminars in Fetal and Neonatal Medicine

Volumn 13, Issue 1, 2008, Pages 44-52

  Tin, Win ^a   Wiswell, Thomas E ^b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b FLORIDA HOSPITAL   (United States)

Author keywords

Adjunctive therapy; Chronic lung disease (CLD); Preterm; Respiratory distress syndrome (RDS)

Indexed keywords

ALPHA TOCOPHEROL; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIURETIC AGENT; FUROSEMIDE; IBUPROFEN; INDOMETACIN; IPRATROPIUM BROMIDE; METHYLXANTHINE; NITRIC OXIDE; RETINOL; SALBUTAMOL; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; SURFACTANT; THIAZIDE DIURETIC AGENT;

ARTICLE; CEREBRAL PALSY; CHILD DEATH; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; DIURETIC THERAPY; DRUG SAFETY; HUMAN; INCIDENCE; LUNG DYSPLASIA; NEONATAL RESPIRATORY DISTRESS SYNDROME; OXYGEN THERAPY; PREMATURITY; RISK REDUCTION; SURVIVAL TIME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; BRONCHOPULMONARY DYSPLASIA; CHOLINERGIC ANTAGONISTS; CROMOLYN SODIUM; CYCLOOXYGENASE INHIBITORS; DIURETICS; FREE RADICAL SCAVENGERS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; NITRIC OXIDE; OXYGEN INHALATION THERAPY; SUPEROXIDE DISMUTASE; VITAMINS; XANTHINES;

EID: 37349052408     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2007.09.008     Document Type: Article

References (77)

1. Weis C.M., Cox C.A., and Fox W.W. Oxygen therapy. In: Spitzer A.R. (Ed). Intensive care of the fetus and newborn (1996), Mosby, St. Louis 538-545
2. Tin W., and Hey E. The medical use of oxygen: a century of research in animals and humans. Neo Reviews 4 (2003) e340-e349
3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust ii (1951) 48-50
4. Askie L.M., and Henderson-Smart D.J. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev 2 (2000) CD001077
5. Northway W.H., Rosan R.C., and Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 267 (1967) 357-368
6. Saugstad O.D. Bronchopulmonary dysplasia - oxidative stress and oxidants. Semin Neonatol 8 (2003) 39-49
7. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105 (2000) 295-310
8. Askie L.M., Henderson-Smart D.J., Irwig L., and Simpson J.M. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349 (2003) 959-967
9. Flynn J.T., Bancalari E., Snyder E.S., Goldberg R.N., Feuer W., et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 326 (1992) 1050-1054
10. Tin W., Milligan D.W.A., Pennefather P.M., and Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child 84 (2001) F106-F110
11. Chow L., Wright K.W., and Sola S. Can changes in clinical practice decrease the incidence of severe retinopathy in very low birth weight infants?. Pediatrics 111 (2003) 339-345
12. Anderson C.G., Benitz W.E., and Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol 24 (2004) 164-168
13. 2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res 51 (2002) A350
14. Bradley S., Anderson K., Tin W., et al. Early oxygen exposure and outcome at 10 years in babies of less than 28 weeks gestation. Pediatr Res 55 (2004) A373
15. Poets C., Arand J., Hummler H., et al. Retinopathy of prematurity: a comparison between two centers aiming for different pulse oximetry saturation levels. Biol Neonate 84 (2003) A267
16. Vijayakumar E., Ward G.J., Bullock C.E., and Patterson M.L. Pulse oximetry in infants <1500 gm birth weight on supplemental oxygen: a national survey. J Perinatol 17 (1997) 341-345
17. Tin W., and Wariyar U. Giving small babies oxygen: 50 years of uncertainty. Semin Neonatol 7 (2002) 361-367
18. Silverman W.A. A cautionary tale about supplemental oxygen: the albatross of neonatal medicine. Pediatrics 113 (2004) 394-396
19. Millar D., and Schmidt B. Controversies surrounding xanthine therapy. Semin Neonatol 9 (2004) 239-244
20. Weinberg B.A., and Bealer B.K. The world of caffeine: the science and culture of the world's most popular drug (2002), Routledge, Taylor and Francis, New York/London
21. Davi M.J., Sankaran K., Simons K.J., Simons F.E., Seshia M.M., et al. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr 92 (1978) 91-95
22. Von Poblotzki M., Rieger-Fackeldey E., and Schulze A. Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000 g of birth weight. Early Hum Dev 72 (2003) 47-55
23. 2 on 'inspiratory drive' and 'effective' timing in preterm infants. Early Hum Dev 5 (1981) 63-70
24. Henderson-Smart D.J., and Steer P.A. Prophylactic methylxanthine for prevention of apnea in preterm infants. Cochrane Database Syst Rev 2 (1999) CD000432
25. Henderson-Smart D.J., and Steer P. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database Syst Rev 4 (2000) CD000075
26. Henderson-Smart D.J., and Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 3 (2001) CD000140
27. Henderson-Smart D.J., and Davis P.G. Prophylactic methylxanthines for extubation in preterm infants. Update of Cochrane Database Syst Rev 2000;(2):CD000139. Cochrane Database Syst Rev 1 (2003) CD000139
28. In: Hey E. (Ed). Neonatal formulary. 4th ed. (2003), BMJ Books, London
29. Schmidt B., Roberts R.S., Davis P., Doyle L.W., Barrington K.J., et al. Caffeine therapy for apnoea of prematurity. N Engl J Med 354 (2006) 2112-2121
30. Schmidt B., Roberts R.S., Davis P., et al. The International Caffeine for Apnea of Prematurity (CAP) trial: preliminary analysis of outcomes at a corrected age of 18-21 months. E-PAS 61 (2007) 5130.1
31. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Early (<96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001146
32. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001144
33. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001145
34. Shah S.S., Ohlsson A., Halliday H.L., et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 1 (2003) CD002058
35. Shah S.S., Ohlsson A., Halliday H.L., and Shah V.S. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 1 (2003) CD002057
36. American Academy of Pediatrics, Committee on Fetus and Newborn; Canadian Pediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002) 330-338
37. Doyle L.W., Davis P.G., Morley C.J., McPhee A., Carlin J.B., and DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomised, controlled trial. Pediatrics 117 (2006) 75-83
38. Doyle L.W., Davis P.G., Morley C.J., McPhee A., Carlin J.B., and DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomised controlled trial of low-dose dexamethasone. Pediatrics 119 (2007) 716-721
39. Doyle L.W., Halliday H.L., Ehrenkranz R.A., Davis P.G., and Sinclair J.C. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 115 (2005) 655-661
40. Brion L.P., and Soll R.F. Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2 (2001)
41. Brion L.P., and Primhak R.A. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 4 (2000) CD001453
42. Brion L.P., Primhak R.A., and Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 3 (2006)
43. Brion L.P., Primhak R.A., and Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Update of Cochrane Database Syst Rev 2000;(3):CD001817. Cochrane Database Syst Rev 1 (2002) CD001817
44. Kinsella J.P., and Abman S.H. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J Pediatr 136 (2000) 717-726
45. Kang J.L., Park W., Pack I.S., Lee H.S., Kim M.J., et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 92 (2002) 795-801
46. Ballard P.L., Gonzales L.W., Godinez R.I., Godinez M.H., Savani R.C., et al. Surfactant composition and function in a primate model of infant chronic lung disease: effect of inhaled nitric oxide. Pediatr Res 59 (2006) 157-162
47. McCurnin D.C., Pierce R.A., Chang L.Y., Gibson L.L., Osborne-Lawrence S., et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 288 (2005) L450-L459
48. Roberts J.D., Polaner D.M., Lang P., and Zapol W.M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 (1992) 818-819
49. Kinsella J.P., Neish S.R., Shaffer E., and Abman S.H. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 (1992) 819-820
50. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;(4):CD000399.
51. Barrington K.J., and Finer N.N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev (2006) CD000509
52. Banks B.A., Seri I., Ischiropoulos H., Merrill J., Rychik J., et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 103 (1999) 610-618
53. Clark P.L., Ekekezie I.I., Kaftan H.A., et al. Safety and efficacy of nitric oxide in chronic lung disease. Arch Dis Child 86 (2002) F41-F45
54. Kinsella J.P., Walsh W.F., Bose C.L., Gerstmann D.R., Labella J.J., et al. Inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure: a randomised controlled trial. Lancet 354 (1999) 1061-1065
55. Field D., Elbourne D., Truesdale A., Grieve R., Hardy P., et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 115 (2005) 926-936
56. Van Meurs K.P., Wright L.L., Ehrenkranz R.A., Lemons J.A., Ball M.B., et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353 (2005) 13-22
57. Schreiber M.D., Gin-Mestan K., Marks J.D., Huo L., Lee G., and Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349 (2003) 2099-2107
58. Kinsella J.P., Cutter G.R., Walsh W.F., Gerstmann D.R., Bose C.L., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355 (2006) 354-364
59. Ballard R.A., Truog W.E., Cnaan A., Martin R.J., Ballard P.J., et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355 (2006) 343-353
60. Stark A.R. Inhaled NO for preterm infants - getting to yes?. N Engl J Med 355 (2006) 404-406
61. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 18 (2001) 1-9
62. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 3 (2002) CD000174
63. Schmidt B., Davis P., Moddemann D., Ohlsson A., Roberts R.S., et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 344 (2001) 1966-1972
64. Shah S.S., and Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 1 (2006) CD004213
65. Denjean A., Paris-Llado J., Zupan V., Debillon T., Kieffer F., et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr 157 (1998) 926-931
66. Ng G.Y., da Silva O., and Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 3 (2001) CD003214
67. Wilkie R.A., and Bryan M.H. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr 111 (1987) 278-282
68. Brundage K.L., Mohsini K.G., Froese A.B., et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis 142 (1990) 1137-1142
69. Yuksel B., and Greenough A. Ipratropium bromide for symptomatic preterm infants. Eur J Pediatr 150 (1991) 854-857
70. Watterburg K.L., and Murphy S. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia. Pediatrics 91 (1993) 803-806
71. Viscardi R.M., Hasday J.D., Gumpper K.F., Taciak V., Campbell A.B., et al. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 156 (1997) 1523-1529
72. Tyson J.E., Wright L.L., Oh W., Kennedy K.A., Mele L., et al. Vitamin A supplementation for extremely-low-birth infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340 (1999) 1962-1968
73. Darlow B.A., and Graham P.J. Vitamin A supplementation for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev 4 (2002) CD00501
74. Wardle S.P., Hughes A., Chen S., and Shaw N.J. Randomised controlled trial of vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child 84 (2001) F9-F13
75. Brion L.P., Bell E.F., and Rughuveer T.S. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 4 (2003) CD003665
76. Rosenfeld W., Evans H., Concepcion L., Jhaveri R., Shaeffer H., et al. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr 105 (1984) 781-785
77. Davis J.M., Rosenfeld W.N., Richter S.E., Parad M.R., Gewolb I.H., et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 100 (1997) 24-30